Passage Bio - רווח נקי למניה (EPS TTM) PASG

Passage Bio, Inc. (PASG) is developing neurogenic therapy in collaboration with the University of Pennsylvania, accelerating global trials. The business's success relies on regulatory approval and interest from pharmaceutical behemoths. The implementation of robotic laboratories optimizes data validation. The YoY percentage change in EPS over 12 months on the GURU.Markets chart reflects profit dynamics, where 28.20 determines the current value of the indicator.

For investors, assessing the sustainability of the Passage Bio (PASG) business model is critical during a period of strict R&D portfolio prioritization and management cost optimization. Analyzing the year-over-year EPS trend (over 12 months) allows for the measurement of the actual rate of change in net profit per share, revealing the company's ability to generate value per share amid external shocks and the anticipation of clinical data.